Dechert Healthcare and Life Sciences Deals Conference 2022

September 22, 2022

BMA House, Tavistock Square, London, WC1H 9JP

Across the world, capital is being invested in PE, VC, M&A, collaboration and licensing deals across the life sciences and healthcare industries, two areas booming with energy driven by scientific revolution and the intersection of healthcare and technology.

For the second year in a row, this one-day event brought together senior pharma, biotech, PE and VC leaders from the life sciences and healthcare industries to network and share their outlook on trends and opportunities across the sectors.

If you have any queries relating to this event, please contact Abby Cook.

If you are a reporter and would like any further information, please contact Dechert's Press Team.

Watch the Individual Panel Recordings

Dechert partnered with BNY Mellon to host the Healthcare and Life Sciences Deals Conference 2022. Held on Thursday, September 22, this year’s in-person event was held at BMA House, Tavistock Square in London. Attendees unable to join us in London had the opportunity to join via our virtual platform, where the conference was streamed live with virtual networking offered.

Welcome and Introduction

Corporate partner Patrick Lyons introduces this year’s hybrid event and provides a brief overview of the current state of the healthcare and life sciences deals market.

Capital Markets: Strategies for Success in Uncertain Times

In our opening panel, corporate partner David Rosenthal moderates a discussion on what makes a company attractive for financing from the perspectives of a venture capitalist, an international investment banker and an issuer.

Accessing U.S. Capital Markets via Depositary Receipts

In this second panel, Karen Bodner, Head of Global Investor Relations Advisory at BNY Mellon moderates a discussion on the benefits of accessing a vast investor base, as well as valuation, execution considerations, governance and structural purpose of the Depositary Receipt mechanism in a U.S. IPO, and post-IPO Investor Relations support.

Licensing and Collaboration: Biopharma Dealmaking Insights

In this third panel, intellectual property partner Thomas Rayski moderates a discussion on the opportunities, challenges and trends in biopharma dealmaking.

Healthcare M&A: State of the Market and Future Trends, Explored

In our closing panel, corporate partner Gregory Schernecke moderates a discussion on the opportunities, challenges and trends at play for healthcare investing in a dynamic marketplace.